New Perspectives on the Risk of Secondary Cancers After CAR T-cell Therapy
Amidst an FDA investigation into secondary cancers after CAR T therapy, researchers show the risk is likely minimal.
Tag: blood cancers
Amidst an FDA investigation into secondary cancers after CAR T therapy, researchers show the risk is likely minimal.
Researchers examined how the molecular features of Hodgkin lymphomas differ between young and older patients.
During his Presidential Address at the AACR Annual Meeting 2024, Philip D. Greenberg discussed research driving immunotherapy forward.
The FDA issued 14 oncology approvals this quarter, including the first tumor-infiltrating lymphocyte therapy.
Researchers at the Blood Cancer Discovery Symposium presented data on multidrug resistance and clinical trial design.
AACR will host the inaugural Blood Cancer Discovery Symposium March 4-6, 2024, featuring experts from all areas of blood...
Our immune systems are equipped to recognize and destroy cancer cells—if they can find them, that is. And with...
For our readers who enjoy learning about the newest tools and strategies in cancer research, the second installment of...
With the approval of new anticancer therapeutics, more treatment options become available for patients. Some therapies are new to...
As the spring weather encourages the planting of flowers, vegetables, and herbs, even careful gardeners may see weeds creeping...